Claudia Galassi
Overview
Explore the profile of Claudia Galassi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
3397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buque A, Bloy N, Petroni G, Jimenez-Cortegana C, Sato A, Iribarren C, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39661487
Background: Hormone receptor (HR)+ breast cancer is poorly responsive to immune checkpoint inhibitors (ICIs). In some settings, radiation therapy (RT) has been shown to mediate immunostimulatory effects and promote ICI...
2.
Campia G, Beltran-Visiedo M, Soler-Agesta R, Sato A, Bloy N, Zhao L, et al.
Methods Cell Biol
. 2024 Oct;
189:153-168.
PMID: 39393881
Dendritic cells (DCs), and especially so conventional type I DCs (cDC1s), are fundamental regulators of anticancer immunity, largely reflecting their superior ability to engulf tumor-derived material and process it for...
3.
Galassi C, Chan T, Vitale I, Galluzzi L
Cancer Cell
. 2024 Oct;
42(11):1825-1863.
PMID: 39393356
According to the widely accepted "three Es" model, the host immune system eliminates malignant cell precursors and contains microscopic neoplasms in a dynamic equilibrium, preventing cancer outgrowth until neoplastic cells...
4.
Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, et al.
Nat Immunol
. 2024 Sep;
25(11):2166.
PMID: 39289560
No abstract available.
5.
Galassi C, Esteller M, Vitale I, Galluzzi L
Trends Cancer
. 2024 Sep;
10(11):1052-1071.
PMID: 39244477
Cancer stem cells (CSCs) are a poorly differentiated population of malignant cells that (at least in some neoplasms) is responsible for tumor progression, resistance to therapy, and disease relapse. According...
6.
Ciccone G, De Luca S, Oderda M, Munoz F, Krengli M, Allis S, et al.
JAMA Netw Open
. 2023 Oct;
6(10):e2338039.
PMID: 37847502
Importance: Although active surveillance for patients with low-risk prostate cancer (LRPC) has been recommended for years, its adoption at the population level is often limited. Objective: To make active surveillance...
7.
Vitale I, Galassi C, Galluzzi L
Cell Res
. 2023 Sep;
34(1):7-8.
PMID: 37739994
No abstract available.
8.
Galassi C, Klapp V, Yamazaki T, Galluzzi L
Immunol Rev
. 2023 Sep;
321(1):20-32.
PMID: 37679959
Cancer cells undergoing immunogenic cell death (ICD) can initiate adaptive immune responses against dead cell-associated antigens, provided that (1) said antigens are not perfectly covered by central tolerance (antigenicity), (2)...
9.
10.
Galassi C, Klapp V, Formenti S, Demaria S, Galluzzi L
Essays Biochem
. 2023 May;
67(6):979-989.
PMID: 37199227
Focal radiation therapy (RT) has been successfully employed to clinically manage multiple types of cancer for more than a century. Besides being preferentially cytotoxic for malignant cells over their nontransformed...